Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph phase_1
1
20%
Ph phase_2
4
80%

Phase Distribution

1

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
4(80.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Other(5)

Detailed Status

unknown5

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 11 (20.0%)
Phase 24 (80.0%)

Trials by Status

unknown5100%

Recent Activity

0 active trials
Showing 5 of 5
unknownphase_2

A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT05741021
unknownphase_1

Efficacy and Safety Study of F520 Combined With Lenvatinib in the Treatment of Patients With Advanced Solid Tumors

NCT05740215
unknownphase_2

A Phase Ⅱ Study of F520 in Patients With Urothelial Carcinoma

NCT04636515
unknownphase_2

The Efficacy and Safety of F520 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma (PTCL).

NCT04457830
unknownphase_2

A Study of F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL)

NCT04457869

Clinical Trials (5)

Showing 5 of 5 trials
NCT05741021Phase 2

A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Unknown
NCT05740215Phase 1

Efficacy and Safety Study of F520 Combined With Lenvatinib in the Treatment of Patients With Advanced Solid Tumors

Unknown
NCT04636515Phase 2

A Phase Ⅱ Study of F520 in Patients With Urothelial Carcinoma

Unknown
NCT04457830Phase 2

The Efficacy and Safety of F520 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma (PTCL).

Unknown
NCT04457869Phase 2

A Study of F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL)

Unknown

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5